Carboplatin-Etoposide Combination in Hormone-Resistant Prostate Cancers
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The aim of our study is to assess the efficacy and toxicity of a chemotherapy regimen
combining carboplatin and etoposide in patients with metastatic hormone-resistant prostate
cancer and neuro-endocrine differentiation. Eligible patients are treated with the
combination of carboplatin AUC4 on day 1 and etoposide 100 mg/m2 on day 1, day 2 and day 3
repeated every 3 weeks for a maximum of 6 cycles. Efficacy endpoints include Prostate
Specific Antigen (PSA) and neuro-endocrine marker response (defined as a 50% or greater
decrease from baseline serum values), objective response rate (according to RECIST criteria),
and toxicity.